Abstract

Most studies characterize longitudinal biomarker trajectories by looking forward at them from a commonly used time origin, such as the initial treatment time. For a better understanding of the relationship between biomarkers and disease progression, we propose to align all subjects by using their disease progression time as the origin and then looking backward at the biomarker distributions prior to that event. We demonstrate that such backward-looking plots are much more informative than forward-looking plots when the research goal is to understand the shape of the trajectory leading up to the event of interest. Such backward-looking plotting is an easy task if disease progression is observed for all the subjects. However, when these events are censored for a significant proportion of subjects in the study cohort, their time origins cannot be identified, and the task of aligning them cannot be performed. We propose a new method to tackle this problem by considering the distributions of longitudinal biomarker data conditional on the failure time. We use landmark analysis models to estimate these distributions. Compared to a naïve method, our new method greatly reduces estimation bias. We apply our method to a study for chronic myeloid leukemia patients whose BCR-ABL transcript expression levels after treatment are good indicators of residual disease. Our proposed method provides a good visualization tool for longitudinal biomarker studies for the early detection of disease.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.